Literature DB >> 25393342

Differential signaling by regulatory subunits of phosphoinositide-3-kinase influences cell survival in INS-1E insulinoma cells.

J Schrader1, P Niebel1, A Rossi1, E Archontidou-Aprin1, D Hörsch1.   

Abstract

Class 1A phosphoinositide 3-kinase (PI3K) is essential for beta-cell growth and survival. Although PI3K has been studied extensively in diabetes the effect of alternatively spliced isoforms of the catalytic subunit p85α on beta cell proliferation and survival remains to be defined.We examined expression and signaling of alternatively spliced PI3K regulatory subunits p85α, p55α and p50α in insulinoma cells (INS-1E), an insulin-producing beta cell line. PI3K regulatory isoforms were knocked down by siRNA transfection or overexpressed by adenoviral gene delivery.Knockdown of p85α elevated PI3K activation determined by Akt phosphorylation at baseline and after stimulation with growth factors. In contrast, Akt phosphorylation was inhibited by overexpression of all isoforms of p85α. Correspondingly, p55α and p85α overexpression decreased downstream kinase GSK-3 phosphorylation as well, whereas p50α overexpression resulted in an activation of GSK-3. Moreover, overexpression of p50α and p85α lead to retinoblastoma protein hyperphosphorylation and S-phase entry. Upon challenge of INS-1E cells with a cytotoxic cytokine cocktail, levels of p85α were reduced and p50α was upregulated. Selective overexpression of p50α prevented cytokine induced apoptosis in INS-1E cells.In conclusion, signalling of p50α, p55α and p85α is similar at the level of Akt, but differentially influence downstream GSK-3 activation and cell cycle entry. PI3K isoform p50α induction by cytokines provides a link between regeneration and cell survival under cytotoxic stress in insulin-producing pancreatic beta-cells. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25393342     DOI: 10.1055/s-0034-1390461

Source DB:  PubMed          Journal:  Exp Clin Endocrinol Diabetes        ISSN: 0947-7349            Impact factor:   2.949


  2 in total

1.  The selective PI3Kα inhibitor BYL719 as a novel therapeutic option for neuroendocrine tumors: Results from multiple cell line models.

Authors:  Svenja Nölting; Jakob Rentsch; Helma Freitag; Katharina Detjen; Franziska Briest; Markus Möbs; Victoria Weissmann; Britta Siegmund; Christoph J Auernhammer; Elke Tatjana Aristizabal Prada; Michael Lauseker; Ashley Grossman; Samantha Exner; Christian Fischer; Carsten Grötzinger; Jörg Schrader; Patricia Grabowski
Journal:  PLoS One       Date:  2017-08-11       Impact factor: 3.240

2.  Antagonistic interaction between Nodal and insulin modulates pancreatic β-cell proliferation and survival.

Authors:  Junfeng Li; Zhihong Wang; Liwei Ren; Linling Fan; Wenjuan Liu; Yaojing Jiang; Harry K Lau; Rui Liu; Qinghua Wang
Journal:  Cell Commun Signal       Date:  2018-11-08       Impact factor: 5.712

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.